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Background: Modern chemotherapy and repeat hepatectomy allow to tailor the surgical strategies for the treat-
ment of colorectal liver metastases (CRLM). This study addresses the hypothesis that parenchymal-sparing 
hepatectomy reduces postoperative complications while ensuring similar oncologic outcomes compared to the 
standardized non-parenchymal-sparing procedures. 
Methods: Clinicopathological data of patients who underwent liver resection for CRLM between 2012 and 2019 at 
a hepatobiliary center in Switzerland were assessed. Patients were stratified according to the tumor burden score 
[TBS2 = (maximum tumor diameter in cm)2 + (number of lesions)2)] and were dichotomized in a lower and a 
higher tumor burden cohort according to the median TBS. Postoperative outcomes, overall survival (OS) and 
recurrence-free survival (RFS) of patients following parenchymal-sparing resection (PSR) for CRLM were 
compared with those of patients undergoing non-PSR. 
Results: During the study period, 153 patients underwent liver resection for CRLM with curative intent. PSR was 
performed in 79 patients with TBS <4.5, and in 42 patients with TBS ≥4.5. Perioperative chemotherapy was 
administered in equal rates in both groups (PSR vs. non-PSR) both in TBS ≥4.5 and TBS <4.5. In patients with 
lower tumor burden (TBS <4.5), PSR was associated with lower overall complication rate (15.2% vs. 46.2%, p =
0.009), a trend for lower major complication rate (8.9% vs. 23.1%, p = 0.123), and shorter length of hospital stay 
(5 vs. 9 days, p = 0.006) in comparison to non-PSR. For TBS <4.5, PSR resulted in equivalent 5-year OS (48% vs. 
39%, p = 0.479) and equivalent 5-year RFS rates (44% vs. 29%, p = 0.184) compared to non-PSR. For TBS ≥4.5, 
PSR resulted in lower postoperative complication rate (33.3% vs. 63.2%, p = 0.031), a trend for lower major 
complication rate (23.8% vs. 42.2%, p = 0.150), lower length of hospital stay (6 vs. 9 days, p = 0.005), 
equivalent 5-year OS (29% vs. 22%, p = 0.314), and equivalent 5-year RFS rates (29% vs. 18%, p = 0.156) 
compared to non-PSR. Among all patients treated with PSR, patients undergoing minimal-invasive hepatectomy 
had equivalent 5-year OS (42% vs. 37%, p = 0.261) and equivalent 5-year RFS (34% vs. 34%, p = 0.613) rates 
compared to patients undergoing open hepatectomy. 
Conclusions: PSR for CRLM is associated with lower postoperative morbidity, shorter length of hospital stay, and 
equivalent oncologic outcomes compared to non-PSR, independently of tumor burden. Our findings suggest that 
minimal-invasive PSR should be considered as the preferred method for the treatment of curatively resectable 
CRLM, if allowed by tumor size and location.   
1. Introduction 
Patients with colorectal liver metastases (CRLM) are regularly 
evaluated for curatively-intended hepatectomy and 5-year overall sur-
vival (OS) rates between 55% and 60% can be achieved, if resection of 
the entire tumor burden is feasible combined with perioperative 
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systemic therapy [1]. Modern criteria for technical resectability include 
the ability to perform resection with tumor-free margins (R0) while 
maintaining sufficient future liver remnant (FLR) to avoid postoperative 
liver failure [2,3]. Systemic therapy regimens with modern cytotoxic 
and biologic agents [4] may downstage primary unresectable CLRM and 
enable curative-indented resection. Developments in interventional 
radiology such as portal vein embolization (PVE) may result in signifi-
cant hypertrophy of the FLR thus making extended resections possible 
[5]. Modern surgical techniques including two-stage hepatectomy [6] 
and ALPPS procedure (Associating Liver Partition and Portal Vein 
Ligation) [7] provided liver surgeons with further tools to perform 
anatomic hepatectomy for patients with advanced disease. 
More recently, the concept of parenchymal-sparing resection (PSR) 
has been proposed to achieve complete removal of the entire tumor 
burden in patients with multiple and/or bilateral CLRM without risking 
insufficient FLR and subsequent liver failure [8,9]. PSR may be partic-
ularly beneficial for patients treated with systemic therapy before sur-
gery because of chemotherapy-associated liver disease. In particular, 
neoadjuvant treatment with oxaliplatin-based regimens has been asso-
ciated with chemotherapy-induced hepatic injury known as sinusoidal 
obstruction syndrome (SOS) [10]. SOS correlated with an increased risk 
for postoperative complications including liver failure and bleeding 
[11]. PSR may also be a more effective method to increase technical 
resectability among patients with extended disease since alternative 
methods such as portal-vein embolization (PVE) with two-stage hepa-
tectomy and ALLPS procedure have been associated with tumor pro-
gression [6] and increased postoperative morbidity [12]. Moreover, PSR 
can be favorably performed by laparoscopic techniques enhancing its 
benefits concerning less invasiveness and accelerated recovery after 
surgery [13,14]. 
PSR has potentially several advantages regarding the oncological 
outcome following hepatectomy for CRLM. In case of recurrent disease 
in approximately 45% of patients undergoing hepatectomy for CRLM 
[15], repeat hepatectomy may significantly prolong survival [16]. 
Hence, these patients may benefit on the long-term, if PSR has been 
performed in the first place, sparing as much liver tissue for re-resection 
as possible. On the other hand, several concerns have been raised 
whether PSR increases positive surgical margin rates and the risk for 
tumor recurrence [17,18]. 
Previous studies have evaluated PSR for CRLM, however, these 
studies were either lacking a comparison group [19], or included groups 
with significant differences in regards to the tumor burden [20], or 
compared only selected subgroups of patients such as those with solitary 
[21], bilateral [22], or deep-placed CRLM [23]. 
Therefore, the aim of our study was to compare the postoperative 
outcomes and long-term survivals of patients undergoing PSR with those 
of patients undergoing non-PSR in the entire cohort of consecutive pa-
tients treated in our center for CRLM after stratifying them according to 
their tumor burden using the previously described tumor burden score 
(TBS) [24]. 
2. Methods 
2.1. Patient inclusion criteria 
Clinicopathological data of 153 consecutive patients who underwent 
hepatectomy for CRLM between 2012 and 2019 at the Department of 
Visceral Surgery and Medicine at the Inselspital Bern were collected 
following approval from the Ethics Commission of the Canton of Bern 
(2018–01576). 
Patients were included in the study if curative-intended resection 
was performed. This was defined as the ability to remove all radiologi-
cally evident tumor. Exclusion criteria were patient age <18 years and 
concomitant microwave ablation. 
2.2. Preoperative assessment 
All patients underwent standardized multidisciplinary evaluation 
before surgery including medical history, physical examination, serum 
laboratory tests, and an anesthesia evaluation. Triphasic contrast- 
enhanced computed tomography (CT) or magnetic resonance imaging 
(MRI) with liver-specific contrast agents was performed for tumor- 
staging. The multimodal treatment concept consisting of perioperative 
systemic therapy and hepatectomy was defined within the framework of 
our weekly interdisciplinary tumor board meetings. 
2.3. Surgical procedure 
Following laparotomy or laparoscopy, the peritoneal cavity was 
examined to exclude undetected peritoneal tumor spread. Intraoperative 
ultrasound examination of the liver was routinely performed to confirm 
the exact location of CRLM and guide resection by taking into consid-
eration the relation of liver lesions to portal pedicles and hepatic veins. 
The aim of surgical treatment was to remove all radiologically evident 
disease while preserving sufficient FLR. The surgical strategy concerning 
the type of resection (PSR vs. non-PSR) was individually designed 
depending of the location and extent of the tumor burden as well the 
administration of preoperative chemotherapy, health status of the pa-
tient, and previous operations. In the most recent years, laparoscopic 
resections combined with PSR were increasingly and preferably per-
formed, during the establishment of minimal-invasive surgery in our 
department. 
Parenchymal transections were performed with or without total or 
selective hepatic vascular exclusion combining cavitron ultrasonic sur-
gical aspirator (CUSA®; Valleylab Boulder, CO, USA), surgical energy 
devices such as Harmonic Ace® (Ethicon Inc. Somerville, NJ, USA) in 
Table 1 
Comparison of patient characteristics between patients who underwent PSR vs. 
non-PSR for CRLM.  














Gender, n (%)     0.744 0.028 
Female 4 (31) 28 (35) 3 (16) 19 (45)   




61 62 70 64 0.897 0.021 
(30–79) (36–84) (52–82) (26–83) 
Age >65 years, n 
(%) 




22 26 27 24 0.237 0.060 
(18–30) (13–40) (17–33) (18–38) 
BMI >30 kg/m2, 
n (%) 
0 (0) 13 (17) 5 (26) 6 (14) 0.116 0.262 
ASA physical 
status, n (%)     
0.684 0.108 
1 0 (0) 0 (0) 0 (0) 0 (0)   
2 3 (23) 26 (33) 4 (21) 15 (36)   
3 10 (77) 49 (62) 13 (69) 27 (64)   
4 0 (0) 4 (5) 2 (10) 0 (0)   
Diabetes, n (%) 0 (0) 11 (14) 4 (21) 4 (10) 0.154 0.221 
Cardiovascular 
disease, n (%) 
2 (23) 30 (38) 10 (53) 14 (33) 0.302 0.156 
Pulmonary 
disease, n (%) 
2 (15) 9 (11) 3 (16) 3 (7) 0.683 0.298 
Renal disease, n 
(%) 
0 (0) 9 (11) 4 (21) 2 (5) 0.203 0.050 
TBS, Tumor Burden Score; CRLM, colorectal liver metastases; BMI, body mass 
index; ASA, American Society of Anesthesiologists. 
p1 TBS <4.5: non-PSR vs. PSR. 
p2 TBS ≥4.5: non-PSR vs. PSR. 
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case of laparoscopic procedures, and vascular stapler (Endo GIA™ 
Medtronic; Dublin, Ireland). 
PSR included wedge resections, segmentectomies and bisege-
mentectomies. Non-PSR was defined as resection of 3 or more contig-
uous liver segments according to the Couinaud classification [25]. 
2.4. Postoperative management 
Patients were admitted postoperatively to an intermediate care unit 
or directly to the surgical ward depending on the extent of resection and 
medical preconditions of the patient. Patients were closely monitored 
for postoperative complications including intra-abdominal bleeding and 
liver failure [26]. Postoperative complications within 90 days after 
surgery were graded according to the classification of Clavien and Dindo 
[27]. Major postoperative morbidity was defined as any complication 
≥3a grade and postoperative mortality as grade 5. All patients were 
discussed following surgery at the interdisciplinary tumor board 
meeting and recommendations regarding postoperative treatment or 
tumor surveillance were made. Oncologic follow-up after hepatectomy 
included cross-sectional imaging (CT or MRI) and tumor marker testing 
(carcinoembryonic antigen) every 3 months in the first two years and 
every 12 months after that. 
2.5. Histological evaluation 
Histological assessment by experienced pathologists was routinely 
performed to confirm the diagnosis and extent of CRLM in the resected 
specimens and evaluate the resection margin status. R0 was defined as a 
surgical margin of ≥1 mm free of malignant cells [2]. 
2.6. Statistical analysis 
In order to minimize the effect of tumor extent on the comparisons 
between the two techniques, patients were stratified according to their 
tumor burden using the recently introduced TBS [TBS2 = (maximum 
tumor diameter in cm)2 + (number of lesions)2] [24] and were dichot-
omized by the median TBS in a lower and a higher tumor burden cohort. 
Tumor diameter and number were measured during histologic evalua-
tion. PSR was compared with non-PSR in each tumor burden cohort 
regarding postoperative morbidity, postoperative mortality, OS, and 
recurrence-free survival (RFS). Additionally, groups were compared 
according to patient- and tumor-related characteristics as well as 
surgery-associated variables. Among patients undergoing PSR, onco-
logic outcomes were also compared according to the surgical technique 
performed (minimal-invasive vs. open hepatectomy). 
Quantitative and qualitative variables were expressed as median 
(range) and frequency (percentage). Comparisons between groups were 
analyzed with the chi-square or Fisher exact test for categorical variables 
and the Mann-Whitney U test for continuous variables, as appropriate. 
Using the Kaplan-Meier method, OS was calculated from the date of 
resection to the date of death or last follow-up and RFS was calculated 
from the date of resection to the date of first recurrence or last follow-up. 
Table 2 
Comparison of tumor and treatment characteristics between patients who underwent PSR vs. non-PSR for CRLM.  
Variable TBS <4.5 TBS ≥4.5 p1 p2 
non-PSR PSR non-PSR PSR 
(n = 13) (n = 79) (n = 19) (n = 42) 
Location of primary, n (%)     0.680 0.893 
Colon 9 (69) 59 (75) 13 (68) 28 (67)   
Rectum 4 (31) 20 (25) 6 (32) 14 (33)   
Synchronous CRLM, n (%) 9 (69) 45 (57) 11 (58) 24 (57) 0.408 0.957 
Tumor burden score, median (range) 3.6 3.0 6.8 6.8 0.120 0.846 
(2.4–4.3) (1.0–4.4) (4.5–18.5) (4.5–17.9) 
CRLM location, n (%)     0.900 0.957 
Superficial 10 (77) 62 (78) 8 (42) 18 (43)   
Deep 3 (23) 17 (22) 11 (58) 24 (57)   
Solitary CRLM, n (%) 8 (62) 43 (54) 7 (37) 14 (33) 0.635 0.791 
Bilateral CRLM, n (%) 5 (39) 24 (30) 6 (32) 22 (52) 0.561 0.131 
Preoperative chemotherapy, n (%) 10 (77) 62 (79) 13 (68) 33 (79) 0.900 0.398 
T stage of primary, n (%)     0.032 0.392 
1 1 (8) 2 (2) 1 (5) 2 (5)   
2 2 (15) 4 (5) 3 (16) 4 (9)   
3 9 (69) 48 (61) 12 (63) 23 (55)   
4 1 (8) 25 (32) 3 (16) 13 (31)   
N stage of primary, n (%)     0.503 0.532 
0 6 (46) 27 (34) 6 (32) 19 (45)   
1 4 (31) 31 (39) 9 (47) 14 (33)   
2 3 (23) 21 (27) 4 (21) 9 (22)   
Poor tumor differentiation of primary (G3), n (%) 2 (15) 7 (9) 0 (0) 3 (7) 0.376 0.735 
Minimal-invasive hepatectomy, n (%) 4 (31) 36 (46) 2 (11) 8 (19) 0.321 0.009 
Positive resection margins, n (%) 1 (8) 10 (13) 4 (21) 8 (19) 0.604 0.892 
Surgical technique, n (%)     <0.001 <0.001 
Right hepatectomy 8 (62) 0 (0) 13 (69) 0 (0)   
Extended right Hepatectomy 0 (0) 0 (0) 1 (5) 0 (0)   
Left hepatectomy 5 (38) 0 (0) 5 (26) 0 (0)   
Bisegmentectomy + wedge-resection 0 (0) 1 (1) 0 (0) 2 (5)   
Segmentectomy + wedge-resection 0 (0) 2 (3) 0 (0) 1 (2)   
Bisegementectomy 0 (0) 14 (17) 0 (0) 10 (24)   
Segmentectomy 0 (0) 2 (3) 0 (0) 0 (0)   
Wedge-resection 0 (0) 60 (76) 0 (0) 29 (69)   
Duration of operation, minutes, median (range) 267 149 176 171 0.001 0.709 
(71–366) (28–499) (75–820) (75–565) 
Postoperative chemotherapy, n (%) 3 (23) 10 (13) 4 (21) 4 (10) 0.379 0.568 
TBS, Tumor Burden Score; CRLM, colorectal liver metastases; OH, open hepatectomy; MIH, minimal-invasive hepatectomy. 
p1 TBS <4.5: non-PSR vs. PSR. 
p2 TBS ≥4.5: non-PSR vs. PSR. 
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Table 3 
Comparison of outcomes between patients who underwent PSR vs. non-PSR for CRLM.  
Variable TBS <4.5 TBS ≥4.5 p1 p2 
non-PSR PSR non-PSR PSR 
(n = 13) (n = 79) (n = 19) (n = 42) 
Length of ICU stay, days, median (range) 2 2 2 2 0.672 0.197 
(0–3) (0–9) (0–9) (0–4) 
Length of hospital stay, days, median (range) 9 5 9 6 0.006 0.005 
(2–13) (2–37) (4–34) (2–50) 
90-day complications, n (%) 6 (46) 12 (15) 12 (63) 14 (33) 0.009 0.031 
90-day major complications, n (%) 3 (23) 7 (9) 8 (42) 10 (24) 0.129 0.150 
90-day mortality, n (%) 0 (0) 0 (0) 1 (5) 1 (2) 1.000 0.562 
Postoperative liver failure, n (%) 0 0 1 (5) 0 1.000 0.127 
Postoperative bleeding, n (%) 1 (8) 2 (3) 1 (5) 2 (5) 0.548 0.898 
Need for transfusion, n (%) 4 (31) 8 (10) 6 (32) 8 (19) 0.042 0.285 
Wound infection, n (%) 1 (8) 3 (4) 2 (11) 5 (12) 0.526 0.877 
Organ/space infection, n (%) 1 (8) 0 2 (10.5) 1 (2.4) 0.014 0.177 
Urinary tract infection, n (%) 0 1 (1) 0 0 0.685 1.000 
Pneumonia, n (%) 0 0 1 (5) 0 1.000 0.137 
Intrahepatic recurrence, n (%) 7 (54) 32 (41) 9 (47) 20 (48) 0.263 0.568 
Repeat hepatectomy for patients with intrahepatic recurrence, n (%) 4 (57) 18 (56) 4 (44) 10 (50) 0.722 1.000 
Microwave ablation for patients with intrahepatic recurrence, n (%) 3 (43) 9 (28) 2 (22) 3 (15) 0.548 0.534 
TBS, Tumor Burden Score; CRLM, colorectal liver metastases; ICU, intensive care unit. 
p1 TBS <4.5: non-PSR vs. PSR. 
p2 TBS ≥4.5: non-PSR vs. PSR. 
Table 4 
Univariate and multivariate analysis of factors associated with postoperative complications following hepatectomy for CRLM in the entire study cohort.   
Postoperative complications No postoperative complications UV MVa 
Variable (n = 44) (n = 109) p p OR (95% CI) 
Age >65 years, n (%) 23 (52) 51 (47) 0.540   
Male gender, n (%) 32 (73) 67 (62) 0.189   
BMI >30 kg/m2, n (%) 8 (18) 16 (15) 0.591   
ASA-Score ≥3, n (%) 32 (73) 73 (67) 0.489   
Primary tumor located in colon, n (%) 31 (71) 78 (72) 0.892   
Earlier abdominal operation, n (%) 38 (86) 101 (93) 0.223   
Solitary tumor, n (%) 15 (34) 57 (52) 0.042 0.152 0.6 (0.2–1.2) 
Synchronous CRLM, n (%) 29 (66) 60 (55) 0.219   
TBS ≥4.5, n (%) 26 (59) 35 (32) 0.002 0.081 2.0 (0.9–4.5) 
Deep tumor location, n (%) 20 (46) 35 (32) 0.121   
Bilateral tumor, n (%) 19 (43) 38 (35) 0.337   
Minimal-invasive hepatectomy, n (%) 10 (23) 51 (47) 0.006 0.035 0.4 (0.2–0.9) 
Parenchymal sparing resection, n (%) 26 (59) 95 (87) <0.001 0.011 3.2 (1.3–7.8) 
Neoadjuvant chemotherapy, n (%) 33 (75) 85 (78) 0.692   
Adjuvant chemotherapy, n (%) 6 (14) 20 (18) 0.484    
a Logistic regression multivariate analysis (MV) included all variables with p < 0.05 in univariate analysis (UV). TBS, Tumor Burden Score; CRLM, colorectal liver 
metastases; BMI, body mass index; ASA, American Society of Anesthesiologists. 
Fig. 1. Overall survival of patients with TBS <4.5 who underwent PSR vs. non-PSR for CRLM.  
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Multivariate analysis of factors associated with postoperative com-
plications in the entire cohort was performed using a logistic regression 
model with backward elimination. Multivariate analysis was also per-
formed to identify factors that are independently associated with OS in 
the entire cohort using a Cox regression model with backward 
elimination. 
P < 0.05 was considered statistically significant. Statistical analysis 
was performed using SPSS Statistics version 25 (IBM, Armonk, New 
York, USA). 
3. Results 
3.1. Patient characteristics 
During the study period, 153 patients underwent curative-intended 
liver resection for CRLM. TBS was calculated for every patient and the 
median TBS of 4.5 was used to stratify patients in a lower (TBS <4.5) and 
a higher tumor burden (TBS ≥4.5) cohort. In the TBS <4.5 cohort, 13 
patients and 79 patients underwent non-PSR and PSR, respectively. 
Among patients with TBS ≥4.5, 19 patients were treated with non-PSR 
and 42 patients with PSR. Comparisons of clinicopathological 
characteristics following PSR vs. non-PSR in the two tumor burden co-
horts are summarized in Table 1. 
Both in the TBS <4.5 and the TBS ≥4.5 cohorts, patients undergoing 
PSR were comparable with patients undergoing non-PSR in regards to 
age >65 years, BMI, American Society of Anesthesiologists (ASA) status, 
comorbidities (metabolic, cardiovascular, pulmonary, renal) (Table 1), 
tumor stage of primary, bilateral CRLM location, and CRLM tumor 
burden (Table 2). The distribution of superficially- and deep-placed 
CRLM (located >30 mm from the liver surface) [28] was equivalent 
between PSR and non-PSR, irrespective of the tumor burden. Addi-
tionally, perioperative chemotherapy was administered in equal rates in 
both groups (PSR vs. non-PSR) both in TBS <4.5 and TBS ≥4.5. There 
was no difference in the implementation of minimal-invasive techniques 
between PSR and non-PSR in the TBS <4.5 cohort (45.6% vs. 30.1, p =
0.321). However, more patients with TBS ≥4.5 underwent 
minimal-invasive PSR than minimal-invasive non-PSR (19% vs. 10%, p 
= 0.009) (Table 2). 
3.2. Postoperative outcomes 
In patients with TBS <4.5 (Table 3), PSR was associated with lower 
Fig. 2. Recurrence-free survival of patients with TBS <4.5 who underwent PSR vs. non-PSR for CRLM.  
Fig. 3. Overall survival of patients with TBS ≥4.5 who underwent PSR vs. non-PSR for CRLM.  
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overall complication rate (15.2% vs. 46.2%, p = 0.009), a trend for 
lower major complication rate (8.9% vs. 23.1%, p = 0.129), and shorter 
length of hospital stay (5 vs. 9 days, p = 0.006) in comparison to non- 
PSR. Postoperative liver failure (0% vs. 0% p = 1.0) was comparable 
between the two techniques and there was a trend for less postoperative 
bleeding after PSR (non-PSR: 8% vs. PSR: 3% p = 0.548). There was no 
postoperative mortality, neither following PSR nor after non-PSR. No 
difference was found between PSR and non-PSR regarding positive 
resection margin status (p = 0.604). 
Among patients with TBS ≥4.5 (Table 3), PSR resulted in lower 
postoperative complication rate (33.3% vs. 63.2%, p = 0.031), a trend 
for lower major complication rate (23.8% vs. 42.2%, p = 0.150), and 
lower length of hospital stay (6 vs. 9 days, p = 0.005). Postoperative 
liver failure (non-PSR: 5% vs. PSR: 0% p = 0.127) and postoperative 
bleeding (non-PSR: 5% vs. PSR: 3%, p = 0.898) did not significantly 
differ between non-PSR and PSR. Postoperative mortality was compa-
rable between the two groups (non-PSR: 5% vs. PSR: 2%, p = 0.562). The 
R1 resection status was not significantly different between PSR and non- 
PSR. TBS ≥4.5 was associated with higher positive resection margin 
rates than TBS <4.5, even though statistical significance was not 
reached (19.7% vs. 10.9%, p = 0.235). 
Multivariate analysis for predictors of postoperative complications in 
the entire study cohort confirmed that PSR was independently associ-
ated with lower postoperative morbidity (Table 4). 
3.3. Oncologic outcomes 
After a median follow-up time of 55 months, among patients with 
TBS <4.5, PSR resulted in equivalent 5-year OS (48% vs. 39%, p =
0.479, Fig. 1) and equivalent 5-year RFS rates (44% vs. 29%, p = 0.184, 
Fig. 2) compared to non-PSR. 
In patients with TBS ≥4.5, PSR was associated with 5-year OS (29% 
vs. 22%, p = 0.314, Figs. 3) and 5-year RFS rates (29% vs. 18%, p =
0.156, Fig. 4) comparable to those after non-PSR. 
Intrahepatic recurrence developed in equal rates following PSR and 
non-PSR both in patients with TBS <4.5 (p = 0.263) and patients with 
TBS ≥4.5 (p = 0.568). Repeat hepatectomy rate and microwave ablation 
rate for intrahepatic recurrence did not differ between PSR and non-PSR 
in both TBS groups (Table 3). 
Multivariate analysis for factors associated with OS in the entire 
study cohort showed that TBS ≥4.5 was an independent predictor for 
worse OS, thus indicating that dichotomization of patients according to 
Fig. 4. Recurrence-free survival of patients with TBS ≥4.5 who underwent PSR vs. non-PSR for CRLM.  
Fig. 5. Overall survival of patients with PSR who underwent open vs. minimal-invasive hepatectomy for CRLM.  
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the median TBS (4.5) was adequate for minimizing the effect of tumor 
extent on the comparison of outcomes between the two surgical tech-
niques (PSR vs. non-PSR). There was no significant difference between 
PSR and non-PSR regarding long-term survival in the entire cohort as 
well (Table 5). 
Among all patients treated with PSR, patients who underwent 
minimal-invasive hepatectomy had equivalent 5-year OS (42% vs. 37%, 
p = 0.261, Fig. 5) and equivalent 5-year RFS rates (34% vs. 34%, p =
0.613, Fig. 6) compared to patients treated with open hepatectomy. 
4. Discussion 
In our current study with 153 consecutive patients treated with 
curative-intended hepatectomy for CRLM, the postoperative and onco-
logic outcomes following PSR were compared with those following non- 
PSR. To increase the comparability of the patient groups, patients were 
stratified according to the TBS in a low and a high tumor burden cohort. 
We showed that in both tumor burden groups, PSR was associated with 
lower postoperative morbidity rates, whereas long-term survivals were 
equivalent. 
Previous studies have compared the oncologic outcomes between 
PSR and non-PSR for CRLM underlining the concern that PSR may be 
less radical and therefore responsible for higher recurrence rates and 
worse overall survivals [29,30]. Whereas older studies predating the era 
of modern chemotherapy showed higher R1 resection rates and worse 
OS following PSR [29], recent studies indicated that PSR is not inferior 
to the non-PSR regarding oncologic outcomes [17,31]. Our study 
confirmed that favorable OS and RFS can be achieved when performing 
PSR, comparable to those after non-PSR, regardless of the tumor burden 
extent defined by the TBS. The oncological radicalness (R0) of PSR in 
our practice was similarly adequate as non-PSR both in patients with 
lower tumor burden (p = 0.604) and patients with extended disease (p =
0.892). Several studies have reported on equal R0 resection margin rates 
between PSR and non-PSR both for open liver surgery [20–22] and 
minimal-invasive hepatectomy [17]. Routine intraoperative ultrasound 
monitoring during liver parenchyma transection to identify the exact 
proximity of liver lesions to neighboring vascular structures and define 
the resection limits [32] as well the use of advanced energy devices and 
high-definition optics in laparoscopic surgery [19] have contributed to 
these results. 
Comparable R1 rates between the two techniques have been related 
to similar intrahepatic recurrence rates in previous studies [23]. Intra-
hepatic recurrence rates were also not different between PSR and 
non-PSR in our study regardless of the tumor burden. However, ac-
cording to a recent study from our group [18], this finding may not be 
associated with the R1 status and therefore with the surgical technique, 
as R1 may be rather a surrogate factor for unfavorable disease without 
influencing the development of recurrence at the intrahepatic resection 
margin. The advantage of PSR over non-PSR in case of intrahepatic 
recurrence is however, the higher possibility to perform repeat hepa-
tectomy [17], without running the risk to suffering postoperative liver 
failure due to insufficient liver remnant. In our study, we did not find a 
difference regarding the rates of repeat hepatectomy of ablation per-
formed following PSR of non-PSR, probably due to the relative low 
patient numbers in each group. Nevertheless, in other studies repeat 
hepatectomy [16,33] or ablation [34] for recurrent CRLM has been 
previously associated with better overall survivals compared to 
chemotherapy or best supportive care and therefore PSR may further 
improve oncologic outcome in the current era of increasing response to 
modern systemic therapy and repeated liver-directed therapies for 
CRLM acknowledged as a chronic disease. 
Another finding of our study were the better postoperative results 
following PSR compared to non-PSR. PSR was associated with lower 
overall postoperative morbidity, a trend for lower major postoperative 
morbidity, and shorter length of hospital stay in both tumor burden 
groups (TBS ≥4.5 and TBS <4.5). Multivariate analysis for predictors of 
postoperative morbidity in the entire study cohort confirmed that PSR 
was significantly associated with less postoperative complications, 
independently of the tumor burden. These results are in concordance 
with previous studies confirming that PSR is a feasible and safe tech-
nique [35,36] not only for patients with solitary lesions [21] but also for 
patients with multiple [17], bilobar [22], and deep-placed [23] CRLM. 
Postoperative liver failure which remains the main cause for post-
hepatectomy mortality [37] occurred equally frequently after PSR and 
non-PSR in our study. Thus, postoperative mortality did not differ be-
tween the groups independently of the tumor burden. 
Table 5 
Univariate and multivariate analysis of factors associated with overall survival 





Variable p p HR (95% 
CI) 
Age, n (%)   0.491   
>65 years 52.3 41    
≤65 years 47.7 45    
Gender, n (%)   0.078   
Female 27.3 NR    
Male 72.7 39    
BMI, n (%)   0.594   
>30 kg/m2 18.2 41    
≤30 kg/m2 81.8 45    
ASA-Score, n (%)   0.205   
≥3 72.7 39    
<3 27.3 NR    
Primary tumor 
location, n (%)   
0.384   
Colon 70.5 45    
Rectum 29.5 35    
Earlier abdominal 
operation, n (%)   
0.759   
Yes 86.4 39    
No 13.6 41    
Number of CRLM, n 
(%)   
0.127   
Solitary 34.1 NR    
Multiple 65.9 39    
Sequence of CRLM, n 
(%)   
0.324   
Synchronous 65.9 45    
Metachronous 34.1 35    
Tumor burden score, n 
(%)   
0.004 0.007 4.1 
(1.5–11.3) 
≥4.5 59.1 26    
<4.5 40.9 57    
CRLM location, n (%)   0.917   
Deep 45.5 41    
Superficial 54.5 39    
Bilateral tumor, n (%)   0.814   
Yes 43.2 45    
No 56.8 41    
Surgical approach, n 
(%)   
0.139   
MIH 22.7 NR    
OH 77.3 39    
Resection technique, n 
(%)   
0.642   
PSR 59.1 37    
Non-PSR 40.9 45    
Neoadjuvant 
chemotherapy, n (%)   
0.733   
Yes 75.0 39    
No 25.0 41    
Adjuvant 
chemotherapy, n (%)   
0.794   
Yes 13.6 20    
No 86.4 41     
a Cox regression multivariate analysis (MV) included all variables with p <
0.05 in univariate analysis (UV). TBS, Tumor Burden Score; CRLM, colorectal 
liver metastases; OH, open hepatectomy; MIH, minimal-invasive hepatectomy; 
PSR, parenchymal-sparing resection; BMI, body mass index; ASA, American 
Society of Anesthesiologists. 
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Improved postoperative outcomes combined with equivalent onco-
logic outcomes may render PSR as the preferred method for the treat-
ment of advanced CRLM compared to other recent surgical 
developments such as two-stage hepatectomy or ALLPS procedure. 
While ALLPS procedure has been associated with significantly high 
major postoperative morbidity and mortality [38], oncologic outcomes 
of PVE and two-stage hepatectomy may be negatively affected by tumor 
progression during the interval for hypertrophy and due to the stimulus 
for liver regeneration [39]. Overall survival in our cohort was lower 
compared to other studies [1]. This may be explained by our current 
patient selection strategy. For patients referred to our tertiary center 
with extended and bilateral tumor burden, we tend to perform 
multi-step PSR combined with chemotherapy between resections and 
thus we may have been able to offer surgery to patients with advanced 
disease, who may have been otherwise deemed unresectable in other 
studies. 
Minimal-invasive hepatectomy has been currently established as the 
standard of care in many specialized hepatobiliary centers [14]. Previ-
ous studies showed that laparoscopic hepatectomy is associated with 
less postoperative complications, shorter length of hospital stay [13,40], 
reduced need for transfusions, and improved R0 resection rates [40]. 
Laparoscopic liver resection was associated with lower median hospital 
stay in our study as well [4 (2–15) vs. 8 (3–50), p < 0.001] compared to 
open hepatectomy. Patients treated with minimal-invasive surgery, have 
fulfilled earlier our discharge criteria such as adequate nutrition, full 
mobilization, normal liver function, and lack of pain symptoms. Lapa-
roscopic techniques have been increasingly performed in our center in 
the last 5 years as part of enhanced recovery after surgery concepts [40], 
thus significantly reducing the length of hospital stay for our patients. 
A recent randomized controlled trial confirmed the surgery-related 
benefits of laparoscopic over open liver surgery among patients under-
going parenchymal-sparing hepatectomy defined as a resection of less 
than 3 consecutive liver segments [13]. Comparison of the same cohort 
has even found no difference in oncologic outcomes between 
minimal-invasive and open hepatectomy [41]. Another recent study 
underlined that laparoscopic PSR for multiple liver lesions provides 
surgical and oncologic outcomes comparable with those of single greater 
resections for multiple CRLM [42]. Our study compared the OS and RFS 
rates of patients undergoing laparoscopic PSR with those treated with 
open PSR and revealed equivalent outcomes between the two tech-
niques. These findings support our current approach that laparoscopic 
PSR should be preferred for patients presenting with resectable CRLM. 
Several limitations should be taken into consideration when 
discussing our results. The findings of this retrospective study have been 
probably impacted by bias regarding the selection of the surgical 
approach. Thus, it is expected that patients with more advanced disease, 
and lesions closer to major vascular vessels may have been preferably 
treated with non-PSR and may have suffered more postoperative 
morbidity which influenced the long-term outcomes. Additionally, dif-
ferences in regards to patient age and comorbidity status between the 
two groups, even though not statistical significant, may have influenced 
the results in favor of PSR. However, we have aimed to minimize the 
effect of tumor extent on our results by stratifying our patients according 
to the established TBS [24,43] creating comparable patient groups for 
low and high tumor burden. Additionally, we showed that the presence 
of superficially-located vs. deep-located CRLM was similar between PSR 
and non-PSR, independently of the tumor burden, which further reduces 
selection bias and strengthens the comparability of the two techniques in 
our study. Future randomized controlled trials comparing PSR with 
non-PSR may further eliminate this bias, however, randomization of 
treatment may be complicated in the current era of multimodal 
personalized precision medicine implementing multiple sessions of 
systemic therapy and repeat hepatectomy for initial and recurrent 
CRLM. 
Furthermore, we are aware that our study included relatively small 
number of patients in each group making a statistical type II error 
possible. This is a result of excluding patients with extrahepatic metas-
tases and patients undergoing concomitant ablation therapy for CRLM in 
an effort to create homogeneous cohorts for the meaningful comparison 
of oncologic outcomes between the two liver surgery approaches. The 
inclusion of simultaneous radiofrequency ablation [17,22] and patients 
with pulmonary metastases [22] in previous studies may have nega-
tively influenced the resection margin rates and long-term survivals [44, 
45]. 
Finally, our study is lacking data on somatic gene mutations to 
investigate the role of tumor biology on decision making regarding the 
appropriate surgical technique. A recent study advocated that PSR 
should be tailored according to tumor biology [30]. While no differences 
on long term survivals between PSR and non-PSR were found among 
patients with KRAS wild-type tumors, PSR was associated with worse 
RFS and worse intrahepatic RFS in patients with KRAS-mutated CRLM. 
Nevertheless, a more recent study including propensity score matching 
analysis indicated that similar oncologic outcomes can be achieved by 
PSR and non-PSR independently of the RAS mutational status [46]. This 
study explains this difference by the fact that although RAS mutation 
accounts for more aggressive disease, the risk for tumor progression is no 
Fig. 6. Recurrence-free survival of patients with PSR who underwent open vs. minimal-invasive hepatectomy for CRLM.  
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specific for intrahepatic recurrence and therefore cannot be prevented 
by non-PSR [47]. This hypothesis may be further supported by our 
recent study, reporting that PSR for CRLM may be justified, even if a R1 
status is deemed very likely in the preoperative assessment, as R1 status 
is probably a surrogate factor for advanced disease and does not have a 
direct impact on the location of intrahepatic or extrahepatic tumor 
recurrence [18]. 
5. Conclusion 
Our study indicated that PSR for CRLM can be performed with lower 
postoperative morbidity achieving equivalent oncologic outcomes 
compared to non-PSR. The benefits of PSR were confirmed regardless of 
the tumor burden. Our findings suggest that minimal-invasive PSR 
should be preferably performed for the treatment of curatively resect-
able CRLM, if allowed by tumor size and location. 
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